- Home
- MIST vs LPTX Comparison
MIST vs LPTX Comparison
Compare MIST & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- LPTX
- Stock Information
- Founded
- MIST 2003
- LPTX 2011
- Country
- MIST Canada
- LPTX United States
- Employees
- MIST N/A
- LPTX N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIST Health Care
- LPTX Health Care
- Exchange
- MIST Nasdaq
- LPTX Nasdaq
- Market Cap
- MIST 145.3M
- LPTX 11.1M
- IPO Year
- MIST N/A
- LPTX N/A
- Fundamental
- Price
- MIST $1.96
- LPTX $0.30
- Analyst Decision
- MIST Strong Buy
- LPTX Hold
- Analyst Count
- MIST 3
- LPTX 1
- Target Price
- MIST $6.33
- LPTX N/A
- AVG Volume (30 Days)
- MIST 1.2M
- LPTX 2.0M
- Earning Date
- MIST 11-11-2025
- LPTX 11-12-2025
- Dividend Yield
- MIST N/A
- LPTX N/A
- EPS Growth
- MIST N/A
- LPTX N/A
- EPS
- MIST N/A
- LPTX N/A
- Revenue
- MIST N/A
- LPTX N/A
- Revenue This Year
- MIST N/A
- LPTX N/A
- Revenue Next Year
- MIST N/A
- LPTX N/A
- P/E Ratio
- MIST N/A
- LPTX N/A
- Revenue Growth
- MIST N/A
- LPTX N/A
- 52 Week Low
- MIST $0.63
- LPTX $0.22
- 52 Week High
- MIST $2.75
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- MIST 66.84
- LPTX 50.81
- Support Level
- MIST $1.75
- LPTX $0.27
- Resistance Level
- MIST $1.83
- LPTX $0.29
- Average True Range (ATR)
- MIST 0.09
- LPTX 0.02
- MACD
- MIST 0.01
- LPTX 0.00
- Stochastic Oscillator
- MIST 90.91
- LPTX 57.20
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.